Drugs / CD-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07072325 | Aug 2025 → Aug 2027 expected | head and neck carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06801470 | Jan 2025 → Jan 2028 expected | cancer | CD (Suzhou) Biopharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06801470 ↗ |
| Route | Intravenous | “CD-001 administered as an intravenous (IV) infusion.” NCT06801470 ↗ |